You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Primary Care Corner with Dr. Geoffrey Modest: Time to screen for lung cancer with CT scanning?

2 Jan, 14 | by EBM

News on New Years Eve Day:

Directly from USPSTF – here is the URL for their formal position: http://www.uspreventiveservicestaskforce.org/uspstf13/lungcan/lungcanfinalrs.htm

and

this is from the Boston Globe:

“Current cigarette smokers ages 55 to 80 who have smoked the equivalent of a pack a day for 30 years, or people who had those same smoking habits within the past 15 years, should be screened, advised the US Preventive Services Task Force, a group created by Congress. Under the federal health law, insurance companies will have to begin covering the $300 to $400 cost of the screening by the end of 2014.”

Here for easy reference is my blog post from 6 months ago on the subject, with review of the most important trial (National Lung Screening Trial):

Recent recommendations by the Am College of Chest Physicians to perform low-dose CT screening of smokers (see DOI: 10.1378/chest.12-2377). these recommendations parallel the interim recommendations of the American Lung Association from 2012

Baseline: lung cancer is common and has generally poor prognosis (esp with lesions greater than stage 1), causing as many deaths as the combo of the next four cancers. one thing to keep in mind is that there are newer therapies that work better than the old ones — targeted to the specific tumor-associated genetic mutations engendered by the cancer (ie, possible that these treatments could change the risk/benefit analysis of screening in the future).  of note, the arena smoking-related morbidity is changing: tobacco companies have seen shrinking local markets (showing that sometimes after decades of obvious connection with lung cancer/persistent denial by the corporations, public health initiatives may work….); as a result,  there has been huge-scale exporting (“dumping”) of cigarettes to developing nations, with likely huge increases in tobacco-related morbidity and mortality in the near future.

Cancer prevention: attempts to prevent cancer in smokers mostly with different antioxidants or anti-inflammatories (eg b-carotene, aspirin, selenium, inhaled steroids, vitamine E, retinoids) have not panned out and are not recommended. preventing smoking initiation is the clearest prevention (though 15% of lung cancers are not smoking related. we do know, however,  from many epidemiologic studies over the decades that cancer risk geometrically increases with multiple insults, including air pollution/environmental exposures and occupational exposures in addition to smoking). for those who smoke,  smoking cessation clearly helps!, with about a 15 year lag to reducing the lung cancer risk to near non-smoker levels (unlike the heart disease risk, which decreases dramatically within 6 months of smoking cessation).

screening methods: old studies have not shown clinical benefit with either CXR of sputum cytology screening.

–low-dose CT screening (LDCT). lots of nodules identified (in 10-50% of smokers — for example, the National Lung Screening Trial Research Team (NSLT)—(see (doi 10.1056/NEJMoa1102873) –screened 27K high risk patients with LDCT and 27K with CXR yearly for 3 years and followed another 3.5 yrs, and found 25% with positive screen on LDCT and 7% with CXR, finding 645 cases/100K person-yrs with LDCT and 572/100K person-yrs with CXR –13% more. most notably, there were 247 lung cancer deaths/100K person-yrs with LDCT and 309 lung cancer deaths/100K person-yrs with CXR, a significant 20% decrease (though not very large absolute numbers – difference of only 62 deaths/100K person-yrs…), and all-cause mortality decreased 7%. the LDCT pickup of cancer was similar each of the 3 years (suggesting that it would be useful to continue screening annually). but, very large number of false positives (>95% of positives were false ones). the vast majority of those with abnormal screens had follow-up radiologic procedures, a small  minority with invasive testing (1.2% of pts not found to have cancer had a biopsy or bronchoscopy).  BUT, given the high number of abnormal screens, the “low-dose” radiation did not remain so low. the CT delivered 1.5 mSv of radiation (vs 8 mSv for regular chest CT). because of the large number of positive LDCT who then received follow up chest CT or PET CT,  the average dose overall for the LDCT cohort was actually 8mSv. the rough calculation is that this degree of radiation exposure (mostly based on atomic bomb and some medical imaging studies) would create one cancer death per 2500 people screened.

–the recommendation:  for smokers and former smokers aged 55-74 who have smoked >30 pack-yrs and either continue smoking or have stopped within the past 15 years should be offered annual LDCT, if comprehensive care can be provided as in the NLST trial.

so, this recommendation, at this point, is by pulmonary specialist organizations, which may have some self-interest (organizationally, or by the individuals involved in crafting the recommendations) to be aggressive (eg, as with the american urology assn and PSA screening).  we may want to wait for a more neutral group (eg USPSTF, though i suspect they will follow suit, given that the NLST is a well-done study). my fundamental concern is that at the same time we are getting recommendations about expensive, intensive, high-tech screening for a largely preventable cancer (and with a significant but low difference in absolute death rates), we in the trenches are getting less and less support for programs to prevent or stop smoking (cutbacks in health educators, varying and variable insurance-based support for smoking cessation devices).  In addition, i am very concerned about the additional radiation exposure (will also resend some of my previous emails about risks of radiation exposure).

–i spoke with radiology at BMC (in fact, one of the participants involved in designing and analyzing NLST) who said:

–not ready to do screening yet. need to develop protocols. but will be a low dose CT, probably no more than the 2mSv (as point of reference: CXR is 5-10x less than that).   more later….

geoff

By submitting your comment you agree to adhere to these terms and conditions
You can follow any responses to this entry through the RSS 2.0 feed.

Latest from Evidence-Based Medicine

Latest from EBM